Wexford Capital’s Larimar Therapeutics LRMR Stock Holding History

Wexford Capital’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-69,799	Closed	-$202K	–	436
2025 Q2	$202K	Buy	+69,799	New	+$162K	0.06%	166

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wexford Capital's LRMR Position: Q3 2025 in Review

Wexford Capital sold out of Larimar Therapeutics (LRMR) in Q3 2025, closing a stake of 69,799 shares — an estimated $202K sold.

Wexford Capital first reported a position in LRMR in Q2 2025 and held it in 1 quarter. The position peaked at $202K in Q2 2025. 136 funds tracked by Wall St. Rank hold LRMR as of Q3 2025.

Wexford Capital reported no remaining Larimar Therapeutics position as of Q3 2025 after selling out during the quarter.
Wexford Capital sold 69,799 Larimar Therapeutics shares in Q3 2025, an estimated $202K.
Wexford Capital first reported a position in Larimar Therapeutics in Q2 2025 and held it in 1 quarter.
Wexford Capital's Larimar Therapeutics position peaked at $202K in Q2 2025.
136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2025.

Based on Wexford Capital's 13F filing for Q3 2025, filed 14 Nov 2025.